Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

BACKGROUND: Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute myeloid leukemia (r/r AML), but identification of this subset remains difficult. METHODS: To search for biomarkers o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Epigenetics
Main Authors: Chung, Woonbok, Kelly, Andrew D., Kropf, Patricia, Fung, Henry, Jelinek, Jaroslav, Su, Xiang Yao, Roboz, Gail J., Kantarjian, Hagop M., Azab, Mohammad, Issa, Jean-Pierre J.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647096/
https://ncbi.nlm.nih.gov/pubmed/31331399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0704-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados